Press review

 - 

Germany launches 'global health hub' to tackle range of diseases, boost healthcare digitilisation

Country : Germany, U.S., UK, Europe

Keywords :
BERLIN, 22 Feb (APM) - Minister of Health Jens Spahn has launched the 'Global Health Hub Germany', a network to combat a range of diseases and advance prevention projects worldwide, reported Frankfurter Allgemeine Zeitung (FAZ) on Tuesday (p16).
The network includes 200 partners - health organisations, foundations, non-governmental organisations, science and academia and healthcare companies. The aim is to make substantial advances against tropical diseases, cancer and antibiotic resistance, as well as digitalisation in healthcare worldwide.

EMA suffers major financial hit over London HQ lease

The European Medicines Agency will not be released from its £500 million lease of its London headquarters, which the agency is vacating for new premises in Amsterdam, reported FAZ on Thursday (p16) (APMHE 61953).
A British court on Wednesday rejected the early termination of the contract by the EMA, saying that the UK's decision to leave the EU was not a sufficient ground.
The High Court ruled that the authority must continue to fulfil its obligations under the lease. The contract runs until 2039 and is worth about £500 million (€575 million).

Fresenius expects to launch Humira biosimilar in 2019

German healthcare group Fresenius expects to launch its biosimilar of AbbVie's Humira (adalimumab) Idacio this year, FAZ (p19), Sueddeutsche Zeitung (SZ) (p13), Handelsblatt (p19) and Die Welt (p12) reported on Thursday (APMHE 61963).
"Biosimilars will bring a considerable growth in sales and earnings during the upcoming decade," said Fresenius chief executive Stephan Sturm during the earnings conference call on Wednesday, Handelsblatt wrote.
Sturm said that he intended to regain investors' trust after a deal to acquire U.S. generics maker Akorn was stopped by Fresenius in February 2018, which cost a high double-digit million-euros sum, SZ said.

German payer testing e-prescriptions

German major payer TK is about to start testing e-prescriptions in the Hamburg city district of Wandsbek, Die Welt reported on Tuesday (p13).
Over an 18-month period, physicians will send Data Matrix barcodes to patients' smart phones that will be scanned in pharmacies, which would reduce the administrative burden for both physicians and pharmacies, Die Welt reported.

J&J's depression spray backed by FDA

Johnson & Johnson's experimental nasal spray Spravato (esketamine) for treatment-resistant depression was backed by 14 of 17 advisers to the U.S. Food and Drug Administration, Die Welt reported on Sunday (p20) (APMHE 61843).
Spravato is a chemical mirror image of anaesthetic ketamine. Researchers have found that other psychoactive substances besides ketamine can be used for depression treatment, such as lysergic acid diethylamide (LSD), Die Welt said.
so/hm/nh

[HM5PNBGZH]

TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT

Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to our last stories

Request a trial to assess coverage that includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.